CRIS Current Research Information System

GUADAGNUOLO, VIVIANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.925
AS - Asia 6.017
EU - Europa 4.866
AF - Africa 435
Continente sconosciuto - Info sul continente non disponibili 352
SA - Sud America 304
OC - Oceania 9
Totale 18.908
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.789
VN - Vietnam 1.841
SG - Singapore 1.541
CN - Cina 1.376
GB - Regno Unito 1.280
SE - Svezia 701
IT - Italia 699
DE - Germania 654
HK - Hong Kong 368
FR - Francia 314
IN - India 271
RU - Federazione Russa 216
BR - Brasile 207
NL - Olanda 186
IE - Irlanda 182
JP - Giappone 113
TG - Togo 110
ZA - Sudafrica 108
BD - Bangladesh 100
UA - Ucraina 99
NG - Nigeria 96
EE - Estonia 92
FI - Finlandia 91
CH - Svizzera 86
CA - Canada 85
CI - Costa d'Avorio 70
KR - Corea 63
BG - Bulgaria 61
BE - Belgio 53
JO - Giordania 49
AR - Argentina 47
GR - Grecia 41
PH - Filippine 41
IQ - Iraq 34
IR - Iran 30
TH - Thailandia 29
ID - Indonesia 26
ES - Italia 23
MX - Messico 21
TR - Turchia 21
PL - Polonia 20
SC - Seychelles 20
PK - Pakistan 19
AT - Austria 18
UZ - Uzbekistan 17
TW - Taiwan 14
SA - Arabia Saudita 12
EC - Ecuador 11
LB - Libano 9
PE - Perù 9
CL - Cile 8
PY - Paraguay 8
AU - Australia 7
CO - Colombia 7
EU - Europa 7
MY - Malesia 7
CZ - Repubblica Ceca 6
EG - Egitto 6
NI - Nicaragua 6
RO - Romania 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
HR - Croazia 5
JM - Giamaica 5
LT - Lituania 5
MA - Marocco 5
MK - Macedonia 5
PT - Portogallo 5
TN - Tunisia 5
GT - Guatemala 4
IL - Israele 4
KE - Kenya 4
KZ - Kazakistan 4
RS - Serbia 4
VE - Venezuela 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AZ - Azerbaigian 3
CR - Costa Rica 3
ET - Etiopia 3
HN - Honduras 3
PS - Palestinian Territory 3
AL - Albania 2
CY - Cipro 2
DK - Danimarca 2
DZ - Algeria 2
GY - Guiana 2
HU - Ungheria 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
QA - Qatar 2
SI - Slovenia 2
TM - Turkmenistan 2
BH - Bahrain 1
BW - Botswana 1
DM - Dominica 1
Totale 18.554
Salva come PNG Salva come JPEG
Città #
Southend 1.164
Singapore 1.084
Ashburn 756
Dong Ket 660
Chandler 606
Fairfield 539
Ann Arbor 374
San Jose 372
Hong Kong 352
Houston 320
Beijing 303
Ho Chi Minh City 273
Wilmington 269
Seattle 265
Woodbridge 265
Hanoi 236
Santa Clara 229
Cambridge 205
Princeton 200
Dublin 181
Boardman 148
Bologna 135
Lomé 110
New York 102
Los Angeles 101
Tokyo 101
Westminster 101
Nanjing 97
Lauterbourg 95
Padova 94
Council Bluffs 90
Hefei 87
Medford 86
Bern 75
Helsinki 74
Abidjan 70
Abeokuta 61
Sofia 60
Frankfurt am Main 57
Munich 53
Brussels 51
Berlin 48
Amman 47
Bremen 46
Shenyang 46
Da Nang 45
Saint Petersburg 45
São Paulo 44
Dallas 42
Buffalo 41
Nanchang 39
Haiphong 38
Redondo Beach 36
Redwood City 36
San Diego 36
Shanghai 36
Redmond 35
Falls Church 34
Florence 34
Seoul 34
Toronto 34
Turin 34
Hebei 33
Milan 33
Jinan 32
Changsha 30
Guangzhou 24
Jiaxing 24
Tianjin 24
London 23
Zhengzhou 23
Falkenstein 21
Mountain View 20
Phoenix 20
Rome 20
Norwalk 19
Orem 19
Hangzhou 18
Hyderabad 17
Turku 17
Baghdad 16
Jakarta 16
Montreal 16
Hải Dương 15
San Francisco 15
Brooklyn 14
Chicago 14
Paris 14
Haikou 13
Jacksonville 13
Bangkok 12
Chengdu 12
Johannesburg 12
Ningbo 12
Vienna 12
Chennai 11
Düsseldorf 11
Roubaix 11
Amsterdam 10
Atlanta 10
Totale 12.007
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 409
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 320
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 304
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 290
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 278
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 271
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 266
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 257
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 253
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 250
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 247
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 242
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 240
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 235
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 232
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 232
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 225
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 224
A case report of acute myeloid leukemia and neurofibromatosis 1 223
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 221
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 220
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 218
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 216
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 215
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 210
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 210
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 210
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 205
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 205
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 204
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 201
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 198
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 197
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 196
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 195
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 194
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 193
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 191
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 191
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 189
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 187
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 186
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 185
You have accessEx-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 185
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 180
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 180
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 180
Clec12a: A new AML stem cell-associated antigen 179
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 176
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 176
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 176
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 175
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 172
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 172
SNP array reveals a new deletion of JAK2 in AML patients 171
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 169
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 166
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 166
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 164
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 164
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 164
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 161
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 160
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 160
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 158
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 158
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 156
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 155
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 155
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 154
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 153
Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study 153
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 152
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 149
Gene expression signature of aneuploidy in acute myeloid leukemia 146
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 144
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 144
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 144
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 143
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 141
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 137
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 136
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 136
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 134
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 133
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 131
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 131
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 130
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 129
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 125
null 123
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 122
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 120
Molecular Characterization of PAX5 alterations in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) 117
Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL) 113
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells 109
IL-17/IL-10 double-producing T cells: New link between infections, immunosuppression and acute myeloid leukemia 101
Totale 18.745
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.987 0 54 115 185 252 142 58 117 130 155 399 380
2022/20232.493 318 392 106 356 180 196 78 117 392 55 181 122
2023/2024653 28 102 23 61 35 171 52 43 50 28 26 34
2024/20252.244 91 360 183 163 286 76 203 78 19 250 84 451
2025/20265.320 440 303 381 300 624 265 484 202 1.376 511 236 198
2026/2027314 142 172 0 0 0 0 0 0 0 0 0 0
Totale 18.908